Clinical trials: Juvenile Arthritis
Enthesitis-related Arthritis (ERA), Juvenile Psoriatic Arthritis (JPsA)
Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.
The goal of this study is to understand the long-term treatment strategies in children and adolescents diagnosed with ERA or JPsA who received secukinumab and achieved inactive disease and to evaluate the long-term treatment…
- Trial name
- NCT07190053
- Testing
- Secukinumab
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Rheumatoid Arthritis, Uveitis
TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis
This study will investigate the safety and effectiveness of the drug TNFR:Fc to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis.
- Trial name
- NCT00001862
- Testing
- Enbrel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Eye Institute (NEI)
Rheumatoid Arthritis, Spondylitis, Ankylosing
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Introduction: Patients with autoimmune rheumatic diseases (ARDs), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PAs), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), primary…
- Conditions
- Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- RZVRheum (NCT05879419)
- Testing
- Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation
- Where
- Brazil
- Volunteers
- 2,005 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks)…
- Trial name
- NCT07517575
- Testing
- OKZ q4w
- Where
- 14 sites in Russia
- Volunteers
- 71 people
- Sponsor
- R-Pharm International, LLC
Juvenile Idiopathic Arthritis
Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)
This study investigates the efficacy of probiotic VSL#3 as an add on standard care on the activity of the disease in patients with Juvenile Idiopathic Arthritis.
- Trial name
- PERMAJI (NCT03092427)
- Testing
- VSL#3
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal…
- Trial name
- NCT03301883
- Testing
- Tocilizumab, NSAIDs, CSs
- Where
- 10 sites in China
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis, COVID 19
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates…
- Conditions
- Juvenile Idiopathic Arthritis, COVID 19, Treatment
- Trial name
- RHUMAJICOVID (NCT04407923)
- Where
- 8 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Polyarticular Juvenile Rheumatoid Arthritis, Arthritis, Juvenile Idiopathic
Start Time Optimization of Biologics in Polyarticular JIA
STOP-JIA is a PCORI funded prospective observational study which compared the clinical effectiveness and impact on patient reported outcomes of 3 Childhood Arthritis \& Rheumatology Research Alliance (CARRA) consensus derived…
- Trial name
- STOP-JIA (NCT02593006)
- Where
- 55 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Hackensack Meridian Health
Spinal Cord Injuries, Spina Bifida
Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention.
The goal of this clinical trial is to learn about how a participation-based intervention builds capacity of youth with physical disabilities to pursue activities of their choice in the community.
- Conditions
- Spinal Cord Injuries, Spina Bifida, Musculoskeletal Disorder, Juvenile Arthritis
- Trial name
- NCT06007885
- Testing
- Pathways and Resources to Engagement and Participation (PREP)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University
Juvenile Idiopathic Arthritis
Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
The best treatment plan for Juvenile Idiopathic Arthritis (JIA) is often complicated. Patients and clinicians often don't know what is the best treatment strategy for a given patient at a given time.
- Trial name
- NCT02524340
- Where
- United States
- Volunteers
- 465 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glucocorticoid-Associated Osteopenia and Osteoporosis
Alendronate Osteoporosis Study
This trial will test the hypothesis that among 20 children and adolescents from Children's Hospital, Boston with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis, juvenile dermatomyositis…
- Trial name
- NCT00277251
- Testing
- Alendronate
- Volunteers
- 20 people
- Sponsor
- Boston Children's Hospital
Osteoporosis
Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis
OBJECTIVES: I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral density of the hip and spine in children with high-turnover idiopathic juvenile osteoporosis.
- Trial name
- NCT00010439
- Testing
- Alendronate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Polyarticular Juvenile Idiopathic Arthritis
An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease affecting children, characterized by chronic synovitis with systemic multi-organ damage.
- Trial name
- NCT05411211
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- AbbVie
Juvenile Idiopathic Arthritis
Clinical, Laboratory and Ultrasound Stratification of Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA), the most common rheumatologic chronic disease in children, is defined as arthritis persisting for at least 6 weeks with no known cause in a patient under the age of 16.
- Trial name
- NCT06007456
- Where
- 2 sites in Italy
- Volunteers
- 80 people
- Sponsor
- IRCCS Burlo Garofolo
Arthritis, Arthritis, Juvenile Idiopathic
Pain in Inflammatory Joint Diseases
Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus…
- Conditions
- Arthritis, Arthritis, Juvenile Idiopathic, Arthritis,Rheumatoid, Arthritis, Reactive
- Trial name
- Nor-Pain (NCT06718569)
- Testing
- Biological or targeted synthetic DMARD
- Where
- Norway
- Volunteers
- 350 people
- Sponsor
- Diakonhjemmet Hospital
Juvenile Idiopathic Arthritis
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)
PART1 Participants in Part 1 (Run-in-Phase) of study will receive tocilizumab (TCZ) (RoActemra/Actemra) 12 milligrams per kilogram (mg/kg) or 8 mg/kg intravenously (IV) every 2 weeks (Q2W) for up to 24 weeks.
- Trial name
- NCT01734382
- Testing
- Tocilizumab
- Where
- 19 sites in United States, Argentina and 8 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis, Malocclusion, Angle Class II
Mandibular Advancement Clear Aligner Treatment in Juvenile Idiopathic Arthritis Subjects
There is currently no information on how mandibular advancement therapy could influence three-dimensionally the condylar and mandibular morphology in growing patients affected by Juvenile Idiopathic Arthritis (JIA).
- Trial name
- NCT05467579
- Testing
- Device: orthodontic - mandibular advancement clear aligner
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Genova
Sjogren's Syndrome, Pediatric ALL
Belimumab After Rituximab in Resistant Primary Juvenile SS
The goal of this clinical trial is to explore the effectiveness of sequential use of rituximab and belimumab in the treatment of resistant primary juvenile Sjogren's syndrome.
- Trial name
- BRRPJS (NCT06410833)
- Testing
- Rituximab, Belimumab
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking Union Medical College Hospital
Juvenile Idiopathic Arthritis, Familial Mediterranean Fever
Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever
Juvenile Idiopathic Arthritis (JIA) and Familial Mediterranean Fever (FMF) are the most common autoimmune and autoinflammatory rheumatic diseases in childhood.
- Conditions
- Juvenile Idiopathic Arthritis, Familial Mediterranean Fever, Healty Controls
- Trial name
- NCT06697028
- Testing
- Usability and Comparison
- Where
- Turkey (Türkiye)
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Chronic Pain
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
- Trial name
- NCT01206907
- Testing
- oxymorphone IR
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company